| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/27/2005 | EP1296665A4 Analgesic and anti-inflammatory compositions containing cox-2 inhibitors |
| 07/27/2005 | EP1289559B1 Combinations of enzyme inhibitor-containing preparations and the use thereof |
| 07/27/2005 | EP1214063B1 Treating cancer using tetraethyl thiuram disulfide |
| 07/27/2005 | EP1187601B1 Novel preparation and administration form comprising an acid-labile proton pump inhibitor |
| 07/27/2005 | EP1143955B1 A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES |
| 07/27/2005 | EP1107733B1 Oral liquid mucoadhesive compositions |
| 07/27/2005 | EP1077716B1 Preparation of a medicament for the treatment of gastroesophageal reflux disease |
| 07/27/2005 | EP1071403B1 Pharmaceutical composition containing a statin and aspirin |
| 07/27/2005 | EP1025236B1 Human checkpoint kinase, hcds1, compositions and methods |
| 07/27/2005 | EP0996436B1 Pharmaceutical formulations containing poorly soluble drug substances |
| 07/27/2005 | EP0977848B1 Human theta subunit of the gaba-a receptor |
| 07/27/2005 | EP0952855B1 Use of hyaluronan in gene therapy |
| 07/27/2005 | EP0935462B1 Photopheresis treatment of leukocytes |
| 07/27/2005 | EP0799051B1 Irrigation solution and use thereof for perioperatively inhibiting pain, inflammation and spasm at a wound |
| 07/27/2005 | CN1646703A Compositions and methods for detection and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene |
| 07/27/2005 | CN1646695A Use of the AXL receptor for diagnosis and treatment of renal disease |
| 07/27/2005 | CN1646692A Genetic products differentially expressed in tumors and use thereof |
| 07/27/2005 | CN1646568A Iron dextrin compounds for the treatment of iron deficiency anaemia |
| 07/27/2005 | CN1646556A Blanched polyamine steroid derivatives |
| 07/27/2005 | CN1646537A Phosphorus-containing compounds & uses thereof |
| 07/27/2005 | CN1646534A Modified fluorinated nucleoside analogues |
| 07/27/2005 | CN1646527A Medicaments containing BETAMIMETICS drugs and a novel anticholinesterase drug |
| 07/27/2005 | CN1646508A 5-substituted 1, 1-dioxo-1, 2, 5-thiazolidine-3-one derivatives as PTP ase 1B inhibitors |
| 07/27/2005 | CN1646480A Derivatives of hydroxyphenyl, a method for preparing thereof and their pharmaceutical composition |
| 07/27/2005 | CN1646168A Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents |
| 07/27/2005 | CN1646167A Treatment of metabolic syndrome |
| 07/27/2005 | CN1646166A Method and composition for potentiating an opiate analgesic |
| 07/27/2005 | CN1646165A Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
| 07/27/2005 | CN1646164A Process for the preparation of a nutrient formulation |
| 07/27/2005 | CN1646163A Administration of agents for the treatment of inflammation |
| 07/27/2005 | CN1646162A Use of an inhibitor or antagonist against tissue factor |
| 07/27/2005 | CN1646156A Strategy for retroviral immunotherapy |
| 07/27/2005 | CN1646155A Cancer therapy |
| 07/27/2005 | CN1646150A Novel use of the extract of processed ginseng and saponin isolated therefrom |
| 07/27/2005 | CN1646143A Combination of a beta-2 adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders |
| 07/27/2005 | CN1646142A Method of treating arrhythmias comprising administration of an A1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside |
| 07/27/2005 | CN1646140A Use of a compound having the ability to release CO in preparation of pharmaceutical compositions for treatment of inflammation |
| 07/27/2005 | CN1646138A Novel therapeutical use of agonist ligands specific to G2A receptor |
| 07/27/2005 | CN1646137A Method for treating and preventing hyperparathyroidism |
| 07/27/2005 | CN1646135A Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention |
| 07/27/2005 | CN1646133A Pharmaceutical combinations of cox-2 inhibitors and opiates |
| 07/27/2005 | CN1646132A Methods of treating patients suffering from movement disorders |
| 07/27/2005 | CN1646130A Treatment of rheumatoid arthritis |
| 07/27/2005 | CN1646129A Dosing regimen for gemcitabine HCV therapy |
| 07/27/2005 | CN1646121A Methods for modulating phototoxicity |
| 07/27/2005 | CN1646120A Antineoplastic combinations |
| 07/27/2005 | CN1646119A Therapeutic methods and compositions involving isoflav-3-ene and isoflavan structures |
| 07/27/2005 | CN1646115A Treating benign prostate hyperplasia with SARMS |
| 07/27/2005 | CN1646112A A herbal molecule as potential anti-leukemic drug |
| 07/27/2005 | CN1646098A Pharmaceutical formulation comprising melatonin |
| 07/27/2005 | CN1646097A Chemosensitizing with liposomes containing oligonucleotides |
| 07/27/2005 | CN1646093A Method and composition for treatment of inflammation and AIDS-associated neurological disorders |
| 07/27/2005 | CN1646078A Composition for cell proliferation |
| 07/27/2005 | CN1644201A Application of folic acid-containing pharmaceutical compositions |
| 07/27/2005 | CN1212155C CD 40 binding molecules and CTL peptides for treating tumors |
| 07/27/2005 | CN1212154C Gel delivery vehicles for anticellular proliferative agent |
| 07/27/2005 | CN1212152C Tumor necrosis factor antagonists and their use in endometriosis |
| 07/27/2005 | CN1212126C Nano hydroxy apatite calcium supplementing agent |
| 07/27/2005 | CN1212117C Medicine composition for treating diabetes mellitus |
| 07/26/2005 | US6922578 Integrated poration, harvesting and analysis device, and method therefor |
| 07/26/2005 | US6921771 Administering a fused aminoquinoline derivative such as (5R)-5-(methylamino)-5,6-dihydro-4H-imidazo(4,5,1-ij) quinoline-2(1H)-thione or pharmaceutically acceptable salts |
| 07/26/2005 | US6921763 Protein kinase inhibitors |
| 07/26/2005 | US6921755 Enhances mucociliary clearance of the nasolacrimal duct and stimulates tear secretion; administering to the ocular surfaces 5'-triphosphates of uridine, cytidine and adenosine and derivatives |
| 07/26/2005 | US6921541 Formulations and methods for providing prolonged local anesthesia |
| 07/26/2005 | US6921539 For therapy of bacterial, fungal, and protozoan infections |
| 07/26/2005 | US6921530 Administering interleukins and immunotherapy to intensify immunology response to infections; prevention or prophylaxis of viral diseases |
| 07/26/2005 | CA2315481C Selective inhibition of aggrecanase in osteoarthritis treatment |
| 07/26/2005 | CA2294562C Hepatitis c inhibitor peptide analogues |
| 07/26/2005 | CA2285203C Compositions containing capsaicin or capsaicin analogues and a local anesthetic |
| 07/21/2005 | WO2005066410A1 Allergen suppressor, allergen-suppression processed fiber and method of producing the same |
| 07/21/2005 | WO2005066357A1 Method of screening molecule associated with psychiatric disorder |
| 07/21/2005 | WO2005066214A1 Hyaluronic acid derivative and drug containing the same |
| 07/21/2005 | WO2005065719A1 Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in combination therapies for the treatment of cancer |
| 07/21/2005 | WO2005065712A2 Complexes having adjuvant activity |
| 07/21/2005 | WO2005065703A1 Novel use of ligand to gpr103-like receptor protein |
| 07/21/2005 | WO2005065696A1 Pharmaceutical compositions comprising an extract of euphorbia prostrata |
| 07/21/2005 | WO2005065685A1 Controlled release pharmaceutical composition comprising an acid-insoluble polymer and a bioadhesive polymer |
| 07/21/2005 | WO2005065678A1 Immunomodulatory combinations |
| 07/21/2005 | WO2005065669A1 Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision |
| 07/21/2005 | WO2005065666A1 Us of a pkc-delta inhibitor for the inhibition of metastatic melanoma |
| 07/21/2005 | WO2005065663A1 Rosiglitazone and metformin formulations |
| 07/21/2005 | WO2005065639A2 Novel pharmaceutical compositions |
| 07/21/2005 | WO2005065308A2 Compositions and methods to treat recurrent medical conditions |
| 07/21/2005 | WO2005065121A2 Methods and compositions for the production of monoclonal antibodies |
| 07/21/2005 | WO2005056027A3 Solvent for biogenic active pharmaceutical ingredients |
| 07/21/2005 | WO2005049827A3 Ppmp as a ceramide catabolism inhibitor for cancer treatment |
| 07/21/2005 | WO2005049012A3 Tryptophan for use in promoting and maintaining abstinence |
| 07/21/2005 | WO2005042021A3 Pharmaceutical composition, containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha-reductase inhibitor |
| 07/21/2005 | WO2005039638A3 Therapeutic agent for heart failure comprising an angiotensin ii receptor antagonist and a matrix metalloproteinase inhibitor |
| 07/21/2005 | WO2005032567A3 Method to treat the side effects associated with non steroidal anti-inflammatory drugs using microorganisms of the genus bifidobacterium |
| 07/21/2005 | WO2004024064A8 Compositions and methods for the diagnosis and treatment of tumor |
| 07/21/2005 | WO2004018648A3 Methods for treating patients and identifying therapeutics |
| 07/21/2005 | WO2003097000A8 Composition for enhancing oral health |
| 07/21/2005 | WO2003090673A3 Compositions and methods for promoting weight loss, thermogenesis, appetite suppression, lean muscle mass, increasing metabolism and boosting energy levels, and use as a dietary supplement in mammals |
| 07/21/2005 | US20050159492 Enhancing bioavailability of oral immediate release tablets for low solubility medicants; respiratory inflammatory disorders |
| 07/21/2005 | US20050159488 D-serine transport antagonist for treating psychosis |
| 07/21/2005 | US20050159485 Prostaglandin and retinoid; low dosage; reduced toxicity and cost |
| 07/21/2005 | US20050159462 Elevates extracellular adenosine concentration for antiinflammatory and immunosuppressive effects; reaction of imidazole-4-carboxamide with a hydroxyalkylbenzoxazole or benzothiazole compound; 1-[4-hydroxy-1-(2-phenyl-4-benzoxazolyl)-3-pentyl]-imidazole-4-carboxamide |
| 07/21/2005 | US20050159461 Treating cancer with a synergistic mixtures; anticarcinogenic agents; epothilone has secondary amide instead of an ester |
| 07/21/2005 | US20050159460 2-[(1R,3S,4S)-1-benzyl-4-t-butoxycarbonylamino-3-hydroxy-5-phenylpentyl]-5-butyl-thiazole; for inhibiting beta-secretase-mediated cleavage of amyloid precursor protein, particularly to inhibit production of A beta peptide; treatment of diseases associated with a pathological form of A beta peptide |